VEGF is the best-characterized angiogenic factor and is recognized as a major element in regulating angiogenesis.[16] Increased VEGF expression has been associated with the development of tumor progression and poor overall survival.[17] As the first approved anti-VEGF drug for treatment of OC by the US Food and Drug Association, bevacizumab is the most widely studied. This evidence concerns the gene VEGFA and neoplasm.